Aminopeptidase N

From Proteopedia

Jump to: navigation, search

The structure of human aminopeptidase N (PDB code 4fyq)

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 Su L, Fang H, Xu W. Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 - 2010): a patent review. Expert Opin Ther Pat. 2011 Aug;21(8):1241-65. doi: 10.1517/13543776.2011.587002. , Epub 2011 May 28. PMID:21619485 doi:http://dx.doi.org/10.1517/13543776.2011.587002
  2. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006 Jan;26(1):88-130. PMID:16216010 doi:http://dx.doi.org/10.1002/med.20044
  3. 3.0 3.1 Xu W, Li Q. Progress in the development of aminopeptidase N (APN/CD13) inhibitors. Curr Med Chem Anticancer Agents. 2005 May;5(3):281-301. PMID:15992355
  4. Bosch BJ, Smits SL, Haagmans BL. Membrane ectopeptidases targeted by human coronaviruses. Curr Opin Virol. 2014 Apr 21;6C:55-60. doi: 10.1016/j.coviro.2014.03.011. PMID:24762977 doi:http://dx.doi.org/10.1016/j.coviro.2014.03.011
  5. Thanawala V, Kadam VJ, Ghosh R. Enkephalinase inhibitors: potential agents for the management of pain. Curr Drug Targets. 2008 Oct;9(10):887-94. PMID:18855623
  6. Lendeckel U, Arndt M, Frank K, Wex T, Ansorge S. Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med. 1999 Jul;4(1):17-27. PMID:10373632
  7. Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci. 2008 May 1;13:3699-713. PMID:18508466
  8. Danziger RS. Aminopeptidase N in arterial hypertension. Heart Fail Rev. 2008 Sep;13(3):293-8. Epub 2007 Nov 16. PMID:18008160 doi:http://dx.doi.org/10.1007/s10741-007-9061-y
  9. doi: https://dx.doi.org/10.2174/092986707780059571‎

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Brenton Horne, Alexander Berchansky

Personal tools